Mirtazapin Stada (Mirtazapine)

Mirtazapine is indicated for depressive disorders and related conditions where enhancement of noradrenergic and serotonergic activity is desired.

• Major depressive disorder: improves mood, sleep quality, and appetite in adult patients.
• Depressive episodes in bipolar I disorder (adjunct therapy): helps alleviate depressive symptoms when used alongside mood stabilizers.
• Depression with prominent insomnia: reduces depressive symptoms while promoting sleep due to its antihistaminic effect.

• Mirtazapine acts as an antagonist at central presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and blocks postsynaptic 5‑HT2 and 5‑HT3 receptors, enhancing serotonergic transmission. It also antagonizes histamine H1 receptors, contributing to its sedative properties and appetite stimulation.

Mirtazapine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Drowsiness or sedation.
• Increased appetite leading to weight gain.
• Dry mouth.
• Constipation.
• Dizziness.

Serious or Rare Side Effects

• Agranulocytosis or severe neutropenia.
• Suicidal thoughts or worsening depression, especially early in therapy.
• Severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome.

Before initiating therapy, clinicians should consider several safety aspects.

• Monitor for worsening depression or suicidal thoughts: especially during initial treatment or dose changes.
• Assess hepatic and renal function: dose adjustments may be needed in impairment.
• Caution in patients with a history of bipolar disorder: risk of switching to mania.
• Avoid abrupt discontinuation: taper under medical supervision to prevent withdrawal.
• Store at room temperature (below 25 °C): keep in original container, protect from moisture and light.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis; a 14‑day washout is required.
• Central nervous system depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression.
• Potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce efficacy.
• Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): risk of serotonin syndrome.
• Anticholinergic drugs: may exacerbate dry mouth and constipation.